Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DNA X's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DNA X's regulatory disclosures and financial reporting.
DNA X, Inc. (SONM) reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain at least $2.5 million of stockholders’ equity. Under a prior Panel decision, the company’s securities remain subject to delisting if it fails to comply with all Nasdaq listing rules through November 18, 2026. In addition, under Nasdaq Listing Rule 5815(d)(4)(B), the company will be under a mandatory panel monitor until August 28, 2027. If during that one-year monitoring period Nasdaq staff again finds the company below the stockholders’ equity requirement, staff must issue a delisting determination without allowing a compliance plan or cure period, although the company could request a new hearing and its securities may then be delisted.
DNA X, Inc. (SONM) disclosed that on August 21, 2026, the compensation committee of its board of directors approved a cash award program ("Substitute Cash Grants") for all board members, including Chief Executive Officer Mike Mulica. These cash awards are being made in lieu of restricted stock units (RSUs) under the company’s 2019 Equity Incentive Plan because no shares remain available under that plan.
The Substitute Cash Grants are structured to closely replicate the company’s existing non-employee director RSU compensation policy. Each grant will equal the fair market value of the company’s common stock underlying the Phantom RSUs at the time of the applicable vesting event and will be paid in cash at that vesting event rather than in stock.
DNA X, Inc. (symbol SONM) reported a sharp strategic shift in the quarter ended June 30, 2026, completing the sale of its legacy rugged phone and hotspot business on January 23, 2026 and focusing on an AI‑driven crypto trading platform. The asset sale generated a $15.3 million pre‑tax gain and contributed to consolidated net income of $5.1 million for the first six months of 2026, compared with a $7.0 million loss a year earlier. Discontinued operations produced $10.3 million income for the six‑month period, while continuing operations recorded a $5.2 million loss with no revenues.
Balance sheet risk has been reduced but not eliminated. Total assets fell to $4.5 million from $43.9 million at December 31, 2025 after removing the sold business, while total liabilities declined to $5.7 million from $50.6 million. Stockholders’ deficit improved from $(8.0) million to $(1.2) million. Cash and cash equivalents were $0.9 million, with $5.5 million net cash used in operating activities in the first half. A related‑party convertible note of $3.1 million was outstanding at quarter‑end, with an associated $0.8 million derivative liability. After June 30, DNA X received $5.0 million of new cash from preferred stock sales to DNA Holdings and exchanged the note into preferred equity, which the company states is expected to fund completion of trading‑platform enhancements and obligations for the year following this report’s filing.
DNA X, Inc., formerly Sonim Technologies Inc., reports it will delay filing its Form 10-Q for the quarter ended June 30, 2026. The delay stems from accounting for a sale of convertible debt and the complexities of consolidating variable interest entities under ASC Topic 810 after terminating a put option related to DNA X, LLC. Following the put right termination, DNA X, LLC must be fully consolidated with DNA X, Inc.’s financial statements, requiring additional time to complete the financial close process. The company expects to file the Form 10-Q within five calendar days of the prescribed due date and preliminarily expects to report a net loss from continuing operations of approximately $1.0 million, versus $1.9 million for the comparable 2025 quarter.
DNA X, Inc. reported that on August 7, 2026 it sold and issued the remaining 416,667 shares of Series B Preferred Stock under its Purchase Agreement, receiving $2.5 million in cash. The company presented a pro forma view showing estimated ending stockholders’ equity of $5,840,000 as of that date.
Based on this pro forma equity, the company believes it now exceeds the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1) and is awaiting Nasdaq’s formal determination. Management notes the pro forma figures are unaudited, based on current estimates and assumptions, and for illustrative purposes only.
DNA X, Inc. reports that investor Laurence W. Lytton beneficially owns 100,521 shares of its common stock, representing 6.8% of the class. This ownership consists of 61,633 shares with sole voting and dispositive power and 38,888 shares with shared voting and dispositive power.
The ownership percentage is based on 1,488,268 shares of common stock outstanding as of May 14, 2026. Lytton also holds warrants to purchase 22,222 additional shares that are excluded from the reported beneficial ownership due to a 4.99% beneficial ownership limitation on those warrants.
DNA X, Inc. amended a prior report to detail a preferred stock financing that improves its stockholders’ equity and supports continued listing on the Nasdaq Capital Market.
On July 8, 2026 the company sold 929,864 shares of Series B Preferred Stock for $2.5 million in cash and cancellation of $3.1 million of a convertible note, and expects to issue another 416,667 shares by August 14, 2026. A pro forma table shows stockholders’ equity moving from deficits in Q1 2026 and estimated Q2 2026 to an estimated $3.8 million as of July 9, 2026, above Nasdaq’s $2.5 million equity requirement, while the company awaits Nasdaq’s formal compliance determination.
DNA X, Inc. entered into a private placement with major holder DNA Holdings Venture to issue 1,346,531 shares of non-voting Series B Convertible Preferred Stock at $6.00 per share, for an aggregate $8.1 million consisting of $5.0 million in cash and cancellation of $3.1 million of note principal.
The Series B Preferred will automatically convert into Common Stock after stockholder approval at an initial conversion price equal to the $6.00 stated value, with customary anti-dilution adjustments and registration rights for resale of the underlying shares. The preferred stock has no general voting rights, a 1x liquidation preference and is not redeemable.
DNA Holdings receives preemptive rights to participate in future financings for 12 months, capped at 50% of each deal. At closing, DNA X also expects to enter a consulting agreement with DNA Holdings, Scott Walker and Brock Pierce, providing 2,494,000 shares of Common Stock as equity consideration, subject to stockholder approval.
DNA X, Inc. files a post-effective amendment to deregister 350,000,000 shares of common stock previously registered for resale by Chardan Capital Markets, LLC.
The amendment states all offerings under Form S-1 (File No. 333-290589) have been terminated and the registrant removes from registration any registered but unsold or unissued securities as of June 8, 2026.